We thank Uslu et al 1 for their comments about our article. 2 In a retrospectively designed study, we assessed the relationship between the platelet-to-lymphocyte ratio (PLR) and the extent/severity of coronary artery disease (CAD) using the Gensini score in association with the inflammatory marker C-reactive protein (CRP) in patients with stable CAD. 2 As stated in the methods section of our article, 2 patients with hematologic diseases and any malignant disease were excluded. Also, all blood samples for complete blood count were collected into standardized tubes containing dipotassium EDTA (K 2 EDTA) just before coronary angiography.
The International Council for Standardization in Hematology advises the use of K 2 EDTA as anticoagulant for hematological testing. 3 Although EDTA-dependent pseudothrombocytopenia (PTCP) mentioned by Uslu et al 1 is a rare phenomenon (ie, *0.1% in the general population), the reliable and timely identification of this artifact is essential to avoid undesired complex diagnostic and therapeutic processes.
Lippi and Plebani 4 recommended that 5 major criteria should be fulfilled to raise the clinical suspicion of EDTA-dependent PTCP: (1) abnormal platelet count, typically <100 Â 10 9 /L; (2) thrombocytopenia in EDTA-anticoagulated samples at room temperature but to a much lesser extent in samples collected with other anticoagulants and/or kept warmed at *37 C; (3) time-dependent fall of platelet count in the EDTA specimen; (4) evidence of platelet aggregates (clumps) in EDTAanticoagulated samples on either automated cell counting or microscopic analysis; and (5) lack of signs or symptoms of platelet disorders. Several alternative anticoagulants have also been evaluated, but most of them are either not applicable to current hematology analyzers or may themselves induce PTCP. In fact, besides EDTA, PTCP was recognized in samples anticoagulated with oxalate, heparin, hirudin, and even citrate. 5, 6 As mentioned earlier, our study data were retrospectively collected and we excluded patients with hematological diseases including thrombocytopenia (<150 Â 10 9 /L). We also excluded patients with malignant diseases in whom EDTA-dependent PTCP has been reported to be high. 7 Thus, EDTA-dependent PTCP is very unlikely for our study population. But this issue should be considered in all studies involving platelet counts.
Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte are indirect indicators of systemic inflammation rather than conventional markers such as CRP. 2 Therefore, we performed a correlation analysis between the PLR and the CRP rather than other markers. Additional proinflammatory cytokines and markers may also be used to compare with PLR.
